TCRX
TScan Therapeutics, Inc.NASDAQHealthcare$1.01+2.97%ClosedMarket Cap: $57.5M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
1.10
P/S
5.73
EV/EBITDA
-0.01
DCF Value
$-4.23
FCF Yield
-236.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
85.6%
Operating Margin
-1315.4%
Net Margin
-1256.8%
ROE
-79.4%
ROA
-56.7%
ROIC
-62.5%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $2.6M | 71.8% | $-23.9M | $-23.0M | $-0.18 | — |
| FY 2025 | $10.3M | 72.2% | $-135.8M | $-129.8M | $-1.00 | — |
| Q3 2025 | $2.5M | 69.5% | $-37.1M | $-35.7M | $-0.28 | — |
| Q2 2025 | $3.1M | 100.0% | $-38.7M | $-37.0M | $-0.28 | — |
| Q1 2025 | $2.2M | 100.0% | $-36.3M | $-34.1M | $-0.26 | — |
| Q4 2024 | $665.0K | 100.0% | $-36.7M | $-35.8M | $-0.30 | — |
| FY 2024 | $2.8M | 100.0% | $-134.8M | $-127.5M | $-1.14 | — |
| Q3 2024 | $1.0M | 100.0% | $-32.6M | $-29.9M | $-0.25 | — |
| Q2 2024 | $536.0K | 100.0% | $-34.1M | $-31.7M | $-0.28 | — |
| Q1 2024 | $566.0K | 100.0% | $-31.4M | $-30.1M | $-0.32 | — |
| Q4 2023 | $7.2M | 82.2% | $-21.4M | $-19.6M | $-0.21 | — |
| FY 2023 | $21.0M | 100.0% | $-93.5M | $-89.2M | $-1.36 | — |